💸 The Tape

On the same day Trulieve began trading on the NYSE — the most tangible proof yet that cannabis rescheduling is reshaping the industry in real time — the opponents of that rescheduling filed their most aggressive legal challenge to date. The timing was not coincidental.

NDASA (the National Drug and Alcohol Screening Association) and MMJ International Holdings filed a joint motion for stay with the U.S. Court of Appeals for the D.C. Circuit on June 9, asking the court to freeze the rescheduling order while the consolidated lawsuits — which also include challenges from SAM, three Republican state attorneys general, and other prohibitionist groups — play out. In plain English: they want the court to put rescheduling on pause and send medical cannabis back to Schedule I until judges decide whether the whole thing was legal in the first place.

Here's what the filing actually argues, how strong the arguments are, and what it means for the industry.

The Core Legal Argument: The Government Broke Its Own Rules

The petitioners' central claim is straightforward: Acting Attorney General Todd Blanche didn't have the legal authority to move medical cannabis to Schedule III the way he did it.

Under the Controlled Substances Act, rescheduling a drug normally requires a lengthy process — the Attorney General must request a scientific evaluation from HHS, receive a binding recommendation on medical and scientific matters, and then conduct a formal rulemaking on the record where outside parties can submit evidence and testimony. That process was already underway when Blanche short-circuited it.

Instead of completing the formal hearing that the DEA itself had convened in 2024, Blanche invoked Section 811(d)(1) of the CSA — a provision that allows the Attorney General to schedule or reschedule a drug without the normal procedures if doing so is necessary to comply with U.S. obligations under the UN Single Convention on Narcotic Drugs. He used that treaty authority to bypass the hearing entirely and issue the rescheduling order directly.

The petitioners argue this violates a 1977 D.C. Circuit ruling called NORML v. DEA, which addressed this exact question almost fifty years ago. In that case, the court held that Section 811(d) is a "limited" exception — it only allows the Attorney General to skip normal procedures to determine the minimum schedule required by treaty obligations. Once that floor is established, any decision to choose between treaty-compliant schedules (for example, choosing Schedule III over Schedule II) must go through the full rulemaking process with HHS review and a formal hearing.

The petitioners point out that the DEA itself acknowledged NORML as binding in its 2024 Notice of Proposed Rulemaking, stating that the D.C. Circuit requires the Attorney General to "select among schedules using the procedures set forth in sections 811(a), 811(b), and 812(b)." The rescheduling order, they argue, does exactly what NORML said the government cannot do.

The Strength of the Argument

This is the most legally serious challenge rescheduling has faced — and it's not close.

The procedural argument has teeth. NORML v. DEA is binding precedent in the D.C. Circuit, and the petitioners are essentially asking the court to enforce its own nearly fifty-year-old ruling that the government has now violated. The rescheduling order itself addresses NORML in a single footnote, arguing that because HHS provided a recommendation in 2023, the requirements of the 1977 decision were satisfied. The petitioners call this "obviously not correct," noting that NORML required both HHS review and a formal rulemaking hearing — not just one or the other.

They also raise a secondary argument about notice-and-comment rulemaking. The rescheduling order didn't just move cannabis between schedules — it created entirely new regulatory provisions, including import-export permit requirements and an elaborate mechanism where the DEA nominally "purchases" and "resells" marijuana from state licensees to comply with the Single Convention's requirement that a government agency monopolize the wholesale trade. The petitioners argue these additional regulatory amendments required standard notice-and-comment procedures under the Administrative Procedure Act, regardless of what Section 811(d) permits for the scheduling change itself.

Standing: Who Actually Gets to Sue Here?

Standing — whether the plaintiffs have a legal right to bring the case at all — is where this motion may quietly fall apart. And recent history isn't on the petitioners' side. A federal judge already dismissed SAM's lawsuit challenging the Medicare CBD pilot program for lack of standing, finding the plaintiffs' alleged injuries were "too distant from the policy to support federal jurisdiction." The same fundamental vulnerability runs through this motion.

NDASA argues its members face concrete economic harm: over 700 employers needing to revise drug testing policies at a combined cost exceeding $700,000, and Medical Review Officer practices potentially losing 35-50% of their revenue as employers drop marijuana from testing panels. On its face, that sounds like the particularized injury courts require. But there's a problem — these costs stem from a business model built entirely around marijuana's Schedule I classification. Courts have historically been reluctant to grant standing to industries whose complaint amounts to "the government changed a policy our revenue depended on." Drug testing companies don't have a constitutional right to a permanent customer base, and the argument that rescheduling harms their business is functionally identical to a typewriter company suing over the invention of computers. The market shifted. That's not an injury the courts are designed to remedy.

The $700,000 in policy revision costs across 700 employers works out to roughly $1,000 per company — a figure that courts may find difficult to characterize as the kind of irreparable, existential harm that justifies freezing a major federal policy action. And the projected revenue declines for MRO practices, while potentially significant, are speculative — they depend on assumptions about how many employers will actually drop marijuana testing, which remains uncertain.

MMJ International Holdings presents an even more tenuous theory: competitive injury from a company that, after eight years and $10 million invested, has never brought a product to market, has never generated commercial revenue, and still has a DEA manufacturing application pending for over seven years without final approval. MMJ argues that rescheduling destroys its competitive advantage by granting federal legitimacy to state-licensed products that bypassed the FDA pathway. But the uncomfortable reality is that MMJ's competitive position was already precarious — an Orphan Drug Designation and two IND applications under clinical hold don't constitute an established market position that rescheduling can destroy. You can't lose market share you never had.

Courts evaluate competitive injury standing by asking whether the plaintiff operates in the same market as the entities benefiting from the challenged action. MMJ's products — if they ever reach patients — would be FDA-approved pharmaceutical cannabinoid therapeutics prescribed through traditional medical channels. State-licensed dispensary products serve a fundamentally different distribution model, patient population, and regulatory framework. Whether a court views these as the "same market" for standing purposes is far from certain, and MMJ's argument that dispensary products are "cannibalizing" its future market share requires accepting that a company with no commercial product, no revenue, and no finalized DEA registration has a cognizable competitive interest to protect.

The broader coalition — including SAM and the three Republican attorneys general from Indiana, Nebraska, and Louisiana — adds political weight but doesn't necessarily solve the standing problem. SAM has now been told by one federal court that its generalized policy objections don't constitute standing. The state attorneys general have a stronger claim through sovereignty-based arguments about disruption to their regulatory frameworks, but whether three states that haven't legalized medical cannabis can claim concrete injury from a federal order that primarily affects the 40 states that have is a question without an obvious answer.

Standing isn't a formality. It's the threshold question that determines whether the court ever reaches the merits. And on the merits, the petitioners may have a strong case built on NORML precedent. But a strong case on the merits is worthless if the court decides you don't have the right to bring it.

The Realistic Assessment

Stays are extraordinary relief, and courts don't grant them lightly. The petitioners need to show likelihood of success on the merits, irreparable harm, and that the public interest favors a pause. The NORML precedent argument is their strongest card. The irreparable harm arguments — drug testing revenue losses and competitive injury to a small pharma company — are real but may not rise to the level courts typically require.

The government will likely argue that disrupting an already-effective rescheduling order — with hundreds of DEA registrations processed, NYSE listings completed, and 280E relief flowing — would cause far greater harm than maintaining the status quo.

The industry should take this challenge seriously. It's the most substantive legal threat rescheduling has faced, built on binding precedent that the government's own agency acknowledged just two years ago. Whether the D.C. Circuit enforces its own 1977 ruling or defers to the government's new interpretation of Section 811(d) could determine the trajectory of federal cannabis policy for the next decade.

The filing landed on the same day cannabis made history on the NYSE. The legal system's response will determine whether that history holds.

📈 Dog Walkers

$HITI ( ▼ 1.72% ) Opens Stores #223 & #224

High Tide keeps adding pins to the map — and the formula behind each one is deliberately repetitive.

The Canadian cannabis retailer announced the opening of a new Canna Cabana in Welland, Ontario and an upcoming location in Calgary, Alberta, bringing the company's total store count to 224 locations across Canada — 99 in Ontario and 92 in Alberta. Both locations follow the same playbook: identify underserved trade areas with limited cannabis competition, anchor alongside high-traffic retail, and plug new customers into the company's membership ecosystem.

The Welland location at 960 Niagara Street marks High Tide's first store in the city, serving a trade area of more than 65,000 residents within five kilometers with minimal existing competition. The Calgary location at 16 MacEwan Drive NW — expected to open June 26 pending regulatory approval — sits in northwest Calgary with no direct cannabis competition in its immediate area and over 60,000 residents within three kilometers.

CEO Raj Grover framed the expansion through the lens of the company's Cabana Club and ELITE membership programs, which he describes as the competitive moat that deepens with every new location: "As our store network and membership ecosystem expand together, we believe we are creating a competitive moat that becomes stronger with every new location we open."

That membership-driven model — combining discount pricing with a loyalty program that drives repeat visits and data capture — is what distinguishes High Tide from cannabis retailers competing purely on price or product selection. Each new store isn't just a revenue node; it's a member acquisition point that feeds the broader network.

For a company that recently flagged concerns about potential manipulative trading activity in its stock and launched a forensic investigation, the operational story remains straightforward: open stores, acquire members, and let the flywheel compound.

$OPTH ( ▼ 4.99% ) Ships Psilocybin

The commercial-stage psychedelic pharmaceutical manufacturer announced the completion of its first export of naturally derived psilocybin to the United Kingdom, comprising both biomass and finished 5mg psilocybin capsules to support a planned Phase 2 clinical trial. The trial partner and indication will be announced at a later date.

The capsules use the same formulation already prescribed to patients in Australia for treatment-resistant depression — meaning Optimi is now supplying the same product into both a commercial patient access program and a clinical research pipeline from a single facility. CEO Dane Stevens called that "a rare position, and one we have spent years building."

The shipment was manufactured at Optimi's GMP facility in Princeton, British Columbia, with all stages — cultivation, API extraction, encapsulation, and packaging — completed in-house under the company's Health Canada Drug Establishment Licence. Export and import authorizations were obtained from Health Canada and the UK Home Office, respectively.

For a psychedelic therapeutics sector where most companies are still navigating preclinical development, Optimi continues to distinguish itself by doing something deceptively simple: manufacturing real products and shipping them to real markets.

The UK is now open. The pipeline keeps expanding.

🗞️ The News

📺 Trade To Black

Village Farms CEO Explains $15M Raise + Inside the CMS CBD Pilot | TTB Presented by Flowhub

• Trulieve Day One: The hosts recap TRLV's first full NYSE trading session — covering price action, volume concentration, and key takeaways from the historic debut of the first U.S. plant-touching cannabis operator on a major exchange.

• Village Farms Capital Strategy: CEO Michael DeGiglio addresses investor questions about the $15M registered direct offering priced near $2 — explaining why the company raised capital after repurchasing $6.4M in shares during Q1 and how it fits the broader U.S. positioning strategy.

• Vantage Standard Series: Rusty Kuchta and Dr. Paul Shields walk through the full operational workflow behind the CMS CBD pilot — from compliant sourcing and pharmaceutical-grade manufacturing to ACO integration and measurable patient outcomes.

• Healthcare Integration: Vantage details how its model aligns with CMS expectations, supports polypharmacy reduction in Medicare populations, and builds real-world evidence inside value-based care frameworks — a roadmap for cannabinoid medicine's entry into mainstream healthcare.